Clover Health Investments (CLOV) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
10 Jun, 2026Opening remarks and agenda
CEO welcomed attendees and introduced key executives and board members present at the meeting.
The meeting was held virtually to increase inclusivity and reach more stockholders.
The business portion was conducted first, followed by a business recap and Q&A session.
Board and executive committee updates
Board members and executive officers were introduced, including the Executive Chairperson and CEO.
A representative from Ernst & Young, the independent auditors, was present.
Shareholder proposals
Three proposals were presented: election of Class 2 Directors, advisory approval of executive compensation for 2025, and ratification of Ernst & Young as auditors for 2026.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Clover Health Investments
- Q1 2026 net income hit $27.3M as revenues soared 62% on strong Medicare Advantage growth.CLOV
Q1 20268 May 2026 - Virtual annual meeting to vote on directors, executive pay, and auditor ratification.CLOV
Proxy filing29 Apr 2026 - Virtual meeting to vote on directors, say-on-pay, and auditor; performance-based pay emphasized.CLOV
Proxy filing28 Apr 2026 - 2025: 38% MA growth, 41% revenue growth, Adjusted EBITDA profit; 2026: 49% revenue growth, GAAP Net Income.CLOV
Q4 20257 Apr 2026 - AI-powered care model delivers top HEDIS scores, rapid growth, and expanding profitability.CLOV
Investor presentation24 Mar 2026 - Strong growth, high retention, and tech-driven care position for 2026 profitability.CLOV
Leerink Global Healthcare Conference 202610 Mar 2026 - AI-driven platform, Star Rating gains, and profitability fuel record growth and 2025 expansion.CLOV
43rd Annual J.P. Morgan Healthcare Conference 20253 Feb 2026 - AI-powered platform drives lower medical costs and scalable growth in Medicare Advantage.CLOV
KeyBanc Capital Markets Technology Leadership Forum2 Feb 2026 - First-ever GAAP net income, 11% revenue growth, and raised guidance on margin gains.CLOV
Q2 20242 Feb 2026